Oppenheimer Increases Mediwound (MDWD) Price Target to $12.00
Mediwound (NASDAQ:MDWD) had its target price lifted by Oppenheimer from $10.00 to $12.00 in a report issued on Monday. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Mediwound’s Q1 2018 earnings at ($0.13) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($0.72) EPS and FY2020 earnings at ($0.41) EPS.
Several other equities research analysts have also issued reports on MDWD. Zacks Investment Research lowered shares of Mediwound from a hold rating to a sell rating in a research report on Thursday, January 18th. ValuEngine lowered shares of Mediwound from a sell rating to a strong sell rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $9.25.
Mediwound stock opened at $5.50 on Monday. Mediwound has a 52-week low of $3.56 and a 52-week high of $8.25. The company has a market cap of $146.06, a P/E ratio of -5.61 and a beta of 0.15.
Several institutional investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC increased its position in shares of Mediwound by 18.2% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 15,500 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Mediwound by 84.6% in the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Mediwound in the third quarter worth $1,538,000. Alyeska Investment Group L.P. acquired a new stake in shares of Mediwound in the third quarter worth $2,140,000. Finally, Meitav Dash Investments Ltd. acquired a new stake in shares of Mediwound in the fourth quarter worth $2,184,000. 32.75% of the stock is owned by institutional investors.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.